SEC Info - Landesman Uri, et al. - ‘4’ for 6/20/14 re: Echo Therapeutics, Inc.

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Nordlicht Mark

(Last)

(First)

(Middle)

152 WEST 57TH STREET

4TH FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Echo Therapeutics, Inc. [ ECTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
6/20/14

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock ⁽¹⁾	6/20/14		P		16,490	A	$2.1996	594,942	I ⁽²⁾	By Platinum Partners Liquid Opportunity Master Fund L.P.
Common Stock ⁽¹⁾	6/23/14		P		85	A	$2.2	595,027	I ⁽²⁾	By Platinum Partners Liquid Opportunity Master Fund L.P.
Common Stock ⁽¹⁾	6/24/14		P		386	A	$2.2	595,413	I ⁽²⁾	By Platinum Partners Liquid Opportunity Master Fund L.P.
Common Stock ⁽¹⁾								1,605,424	I ⁽³⁾	By Platinum Partners Value Arbitrage Fund L.P.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person^*

Nordlicht Mark

(Last)

(First)

(Middle)

152 WEST 57TH STREET

4TH FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Platinum Management (NY) LLC

(Last)

(First)

(Middle)

152 WEST 57TH STREET

4TH FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Platinum Liquid Opportunity Management (NY) LLC

(Last)

(First)

(Middle)

152 WEST 57TH STREET

4TH FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Platinum Partners Liquid Opportunity Master Fund L.P.

(Last)

(First)

(Middle)

152 WEST 57 STREET, 4TH FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Platinum Partners Value Arbitrage Fund, LP

(Last)

(First)

(Middle)

C/O WALKERS CORPORATE SERVICES LIMITED

WALKER HOUSE, 87 MARY STREET

(Street)

GEORGETOWN, GRAND CAYMAN

KY1-9002

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Platinum-Montaur Life Sciences, LLC

(Last)

(First)

(Middle)

152 WEST 57TH STREET

4TH FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

LANDESMAN URI

(Last)

(First)

(Middle)

30 00 47TH AVE

(Street)

LONG ISLAND CITY

11101

(City)

(State)

(Zip)

Explanation of Responses:

(1) This Form 4 is filed jointly by Platinum Partners Value Arbitrage Fund L.P. ("PPVA"), Platinum Partners Liquid Opportunity Master Fund L.P. ("PPLO"), Platinum-Montaur Life Sciences, LLC ("Platinum-Montaur"), Platinum Management (NY) LLC ("Platinum Management"), Platinum Liquid Opportunity Management (NY) LLC ("Platinum Liquid Management"), Mark Nordlicht and Uri Landesman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein.

(2) Securities owned directly by PPLO. Each of Platinum Liquid Management, as the Investment Manager of PPLO, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Liquid Management, may be deemed to beneficially own the securities owned directly by PPLO.

(3) Securities owned directly by PPVA. Each of Platinum Management, as the Investment Manager of PPVA, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Management, may be deemed to beneficially own the securities owned directly by PPVA.

Remarks:

	/s/ Mark Nordlicht	6/24/14
	Platinum Partners Value Arbitrage Fund L.P., By Platinum Management (NY) LLC, as Investment Manager, By /s/ Mark Nordlicht, Chief Investment Officer	6/24/14
	Platinum Partners Liquid Opportunity Master Fund L.P., By Platinum Liquid Opportunity Management (NY) LLC, as Investment Manager, By /s/ Mark Nordlicht, Chief Investment Officer	6/24/14
	Platinum-Montaur Life Sciences, LLC, By Platinum Management (NY) LLC, as Investment Manager, By /s/ Mark Nordlicht, Chief Investment Officer	6/24/14
	Platinum Management (NY) LLC, By /s/ Mark Nordlicht, Chief Investment Officer	6/24/14
	Platinum Liquid Opportunity Management (NY) LLC, By /s/ Mark Nordlicht, Chief Investment Officer	6/24/14
	/s/ Uri Landesman	6/24/14
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

____________ Transaction Code:
P	Open market or private purchase of non-derivative or derivative security.

Landesman Uri, et al. – ‘4’ for 6/20/14 re: Echo Therapeutics, Inc.

On: Tuesday, 6/24/14, at 6:18pm ET · For: 6/20/14 · As: 10% Owner · Accession #: 1140361-14-26587 · File #: 1-35218

Previous ‘4’: ‘4’ on 12/12/13 for 12/10/13 · Next: ‘4’ on 6/27/14 for 6/25/14 · Latest: ‘4’ on 12/22/14 for 12/18/14

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34
Filing Table of Contents

This ‘4’ Document is an XML Data File that may be rendered in various formats:

Landesman Uri, et al. – ‘4’ for 6/20/14 re: Echo Therapeutics, Inc.

On: Tuesday, 6/24/14, at 6:18pm ET · For: 6/20/14 · As: 10% Owner · Accession #: 1140361-14-26587 · File #: 1-35218

Previous ‘4’: ‘4’ on 12/12/13 for 12/10/13 · Next: ‘4’ on 6/27/14 for 6/25/14 · Latest: ‘4’ on 12/22/14 for 12/18/14

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34Filing Table of Contents

This ‘4’ Document is an XML Data File that may be rendered in various formats:

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34
Filing Table of Contents